Literature DB >> 24390813

Treatment of endocrine disorders in the neuroscience intensive care unit.

Janice J Hwang1, David Y Hwang.   

Abstract

OPINION STATEMENT: This review discusses concepts and treatments associated with the most clinically relevant areas of acute endocrine dysfunction amongst patients with common diseases in neuroscience intensive care units (Neuro ICUs). We highlight the following points:• While a thorough work-up for hyponatremia when it is present is always warranted, subarachnoid hemorrhage (SAH) patients who are in a time window concerning for cerebral vasospasm and who are hyponatremic with high urine output are generally thought to have cerebral salt wasting. These patients are typically treated with a combination of continuous hypertonic saline infusion and fludrocortisone.• Diabetes insipidus (DI) is often seen in patients fulfilling death by neurological criteria, as well as in patients with recent pituitary surgery and less often in SAH and traumatic brain injury patients who are not brain dead. Patients with DI in the Neuro ICU often cannot drink to thirst and may require a combination of desmopression/vasopressin administration, aggressive fluid repletion, and serum sodium monitoring.• Diagnosing adrenal insufficiency immediately following pituitary injury is complicated by the fact that the expected atrophy of the adrenal glands, due to lack of a stimulus from pituitary adrenocorticotropic hormone, may take up to 6 weeks to develop. Cosyntropin testing can be falsely normal during this period.• Both hyperglycemia (glucose >200 mg/dL) and hypoglycemia (glucose <50 mg/dL) are strongly associated with neurological morbidity and mortality in ICUs and should be avoided. Glucose concentrations between 120-160 mg/dL can serve as a reasonable target for insulin infusion protocols.• There is no data to suggest that treatment of abnormal thyroid function tests in nonthyroidal illness syndrome/sick euthyroid leads to benefits in either mortality or morbidity. True myxedema coma is a rare clinical diagnosis that is treated with intravenous levothyroxine accompanied by stress-dose steroids.

Entities:  

Year:  2014        PMID: 24390813     DOI: 10.1007/s11940-013-0271-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  49 in total

1.  Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.

Authors:  Phil Edwards; Miguel Arango; Laura Balica; Rowland Cottingham; Hesham El-Sayed; Barbara Farrell; Janice Fernandes; Tamar Gogichaisvili; Nyoman Golden; Bennie Hartzenberg; Mazhar Husain; Mario Izurieta Ulloa; Zouheir Jerbi; Hussein Khamis; Edward Komolafe; Véronique Laloë; Gabrielle Lomas; Silke Ludwig; Guy Mazairac; Maria de los Angeles Muñoz Sanchéz; Luis Nasi; Fatos Olldashi; Patrick Plunkett; Ian Roberts; Peter Sandercock; Haleema Shakur; Caridad Soler; Reto Stocker; Petr Svoboda; Stefan Trenkler; N K Venkataramana; Jonathan Wasserberg; David Yates; Surakrant Yutthakasemsunt
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

Review 2.  Clinical practice. The syndrome of inappropriate antidiuresis.

Authors:  David H Ellison; Tomas Berl
Journal:  N Engl J Med       Date:  2007-05-17       Impact factor: 91.245

3.  Relationship between hyperglycemia and symptomatic vasospasm after subarachnoid hemorrhage.

Authors:  Neeraj Badjatia; Mehmet A Topcuoglu; Ferdinando S Buonanno; Eric E Smith; Raul G Nogueira; Guy A Rordorf; Bob S Carter; Christopher S Ogilvy; Aneesh B Singhal
Journal:  Crit Care Med       Date:  2005-07       Impact factor: 7.598

4.  Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage.

Authors:  Adnan I Qureshi; M Fareed K Suri; Gene Y Sung; Robert N Straw; Abutaher M Yahia; Mustafa Saad; Lee R Guterman; L Nelson Hopkins
Journal:  Neurosurgery       Date:  2002-04       Impact factor: 4.654

5.  Posterior pituitary dysfunction after traumatic brain injury.

Authors:  Amar Agha; Evan Thornton; Patrick O'Kelly; William Tormey; Jack Phillips; Christopher J Thompson
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

6.  Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage.

Authors:  M Tomida; M Muraki; K Uemura; K Yamasaki
Journal:  Stroke       Date:  1998-08       Impact factor: 7.914

7.  Glucose control and mortality in patients with severe traumatic brain injury.

Authors:  Donald E G Griesdale; Marie-Hélène Tremblay; Jonathan McEwen; Dean R Chittock
Journal:  Neurocrit Care       Date:  2009-12       Impact factor: 3.210

8.  Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients.

Authors:  Yaseen M Arabi; Ousama C Dabbagh; Hani M Tamim; Abdullah A Al-Shimemeri; Ziad A Memish; Samir H Haddad; Sofia J Syed; Hema R Giridhar; Asgar H Rishu; Mouhamad O Al-Daker; Salim H Kahoul; Riette J Britts; Maram H Sakkijha
Journal:  Crit Care Med       Date:  2008-12       Impact factor: 7.598

9.  Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.

Authors:  Renda Soylemez Wiener; Daniel C Wiener; Robin J Larson
Journal:  JAMA       Date:  2008-08-27       Impact factor: 56.272

10.  Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage.

Authors:  Marianne Klose; Jannick Brennum; Lars Poulsgaard; Michael Kosteljanetz; Aase Wagner; Ulla Feldt-Rasmussen
Journal:  Clin Endocrinol (Oxf)       Date:  2010-01-23       Impact factor: 3.478

View more
  2 in total

1.  A case of bilateral adrenal haemorrhage following traumatic brain injury.

Authors:  Mervyn Leong; Madhav Pendyala; Joga Chaganti; Suhel Al-Soufi
Journal:  J Intensive Care       Date:  2015-02-03

Review 2.  Diabetes Insipidus after Traumatic Brain Injury.

Authors:  Cristina Capatina; Alessandro Paluzzi; Rosalid Mitchell; Niki Karavitaki
Journal:  J Clin Med       Date:  2015-07-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.